Literature DB >> 28093616

Rare germline alterations in cancer-related genes associated with the risk of multiple primary tumor development.

Rolando A R Villacis1, Tatiane R Basso1, Luisa M Canto1, Maísa Pinheiro1, Karina M Santiago2, Juliana Giacomazzi3, Cláudia A A de Paula1, Dirce M Carraro1, Patrícia Ashton-Prolla3, Maria I Achatz2,4, Silvia R Rogatto5,6,7.   

Abstract

Multiple primary tumors (MPT) have been described in carriers of inherited cancer predisposition genes. However, the genetic etiology of a large proportion of MPT cases remains unclear. We reviewed 267 patients with hereditary cancer predisposition syndromes (HCPS) that underwent genetic counseling and selected 22 patients with MPT to perform genomic analysis (CytoScan HD Array, Affymetrix) aiming to identify new alterations related to a high risk of developing MPT. Twenty patients had a positive family history of cancer and 11 met phenotypic criteria for HCPS. Genetic testing for each of the genes associated with these syndromes revealed negative results for pathogenic mutations. Seventeen rare germline copy number variations (CNVs) covering 40 genes were identified in 11 patients, including an EPCAM/MSH2 deletion in one Lynch syndrome patient. An enrichment analysis revealed a significant number of genes (where the CNVs are mapped) associated with carcinogenesis and/or related to functions implicated with tumor development, such as proliferation and cell survival. An interaction network analysis highlighted the importance of TP53 pathway in cancer emergence. A high number of germline copy-neutral loss of heterozygosity (cnLOH) was identified in nine cases, particularly in two patients. Eighteen genes were covered by both rare CNVs and cnLOH, including 14 related to tumorigenesis and seven genes (ABCC1, KDM4C, KIAA0430, MYH11, NDE1, PIWIL2, and ULK2) specifically associated with cellular growth and proliferation. Overall, we identified 14 cases with rare CNVs and/or cnLOH that may contribute to the risk of MPT development. KEY MESSAGE: CNVs may explain the risk of hereditary cancer syndromes in MPT patients. CNVs affecting genes related to cancer are candidates to be involved in MPT risk. EPCAM/MSH2 deletions should be investigated in patients suspected to have LS. Gene enrichment related to the TP53 network is associated with MPT development. cnLOH and CNVs contribute to the risk of MPT development.

Entities:  

Keywords:  CNV; Hereditary cancer predisposition syndromes; Microarray; Multiple primary tumors; cnLOH

Mesh:

Substances:

Year:  2017        PMID: 28093616     DOI: 10.1007/s00109-017-1507-7

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  49 in total

1.  A child with Li-Fraumeni syndrome: Modes to inactivate the second allele of TP53 in three different malignancies.

Authors:  Brigitte Schlegelberger; Hans Kreipe; Ulrich Lehmann; Doris Steinemann; Tim Ripperger; Gudrun Göhring; Kathrin Thomay; Andreas Rump; Nataliya Di Donato; Meinolf Suttorp
Journal:  Pediatr Blood Cancer       Date:  2015-03-18       Impact factor: 3.167

2.  Increased frequency of 20q gain and copy-neutral loss of heterozygosity in mismatch repair proficient familial colorectal carcinomas.

Authors:  A Middeldorp; R van Eijk; J Oosting; G I Forte; M van Puijenbroek; M van Nieuwenhuizen; W E Corver; D Ruano; T Caldes; J Wijnen; H Morreau; T van Wezel
Journal:  Int J Cancer       Date:  2011-07-15       Impact factor: 7.396

3.  Identification of important long non-coding RNAs and highly recurrent aberrant alternative splicing events in hepatocellular carcinoma through integrative analysis of multiple RNA-Seq datasets.

Authors:  Lu Zhang; Xiaoqiao Liu; Xuegong Zhang; Ronghua Chen
Journal:  Mol Genet Genomics       Date:  2015-12-28       Impact factor: 3.291

Review 4.  Role of non-coding sequence variants in cancer.

Authors:  Ekta Khurana; Yao Fu; Dimple Chakravarty; Francesca Demichelis; Mark A Rubin; Mark Gerstein
Journal:  Nat Rev Genet       Date:  2016-01-19       Impact factor: 53.242

5.  TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells.

Authors:  Annamaria Biroccio; Julien Cherfils-Vicini; Adeline Augereau; Sébastien Pinte; Serge Bauwens; Jing Ye; Thomas Simonet; Béatrice Horard; Karine Jamet; Ludovic Cervera; Aaron Mendez-Bermudez; Delphine Poncet; Renée Grataroli; Claire T'kint de Rodenbeeke; Erica Salvati; Angela Rizzo; Pasquale Zizza; Michelle Ricoul; Céline Cognet; Thomas Kuilman; Helene Duret; Florian Lépinasse; Jacqueline Marvel; Els Verhoeyen; François-Loïc Cosset; Daniel Peeper; Mark J Smyth; Arturo Londoño-Vallejo; Laure Sabatier; Vincent Picco; Gilles Pages; Jean-Yves Scoazec; Antonella Stoppacciaro; Carlo Leonetti; Eric Vivier; Eric Gilson
Journal:  Nat Cell Biol       Date:  2013-06-23       Impact factor: 28.824

Review 6.  Germline copy number variations and cancer predisposition.

Authors:  Ana Cristina Victorino Krepischi; Peter Lees Pearson; Carla Rosenberg
Journal:  Future Oncol       Date:  2012-04       Impact factor: 3.404

7.  Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.

Authors:  Jennifer Saam; Kelsey Moyes; Michelle Landon; Kayon Williams; Rajesh R Kaldate; Christopher Arnell; Richard Wenstrup
Journal:  Oncology       Date:  2014-12-11       Impact factor: 2.935

Review 8.  10 rare tumors that warrant a genetics referral.

Authors:  Kimberly C Banks; Jessica J Moline; Monica L Marvin; Anna C Newlin; Kristen J Vogel
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

Review 9.  Multiple primary cancers as a guide to heritability.

Authors:  Cezary Cybulski; Safia Nazarali; Steven A Narod
Journal:  Int J Cancer       Date:  2014-06-19       Impact factor: 7.396

10.  Rare copy number variants observed in hereditary breast cancer cases disrupt genes in estrogen signaling and TP53 tumor suppression network.

Authors:  Katri Pylkäs; Mikko Vuorela; Meeri Otsukka; Anne Kallioniemi; Arja Jukkola-Vuorinen; Robert Winqvist
Journal:  PLoS Genet       Date:  2012-06-21       Impact factor: 5.917

View more
  3 in total

1.  Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families.

Authors:  Mev Dominguez-Valentin; Sigve Nakken; Hélène Tubeuf; Daniel Vodak; Per Olaf Ekstrøm; Anke M Nissen; Monika Morak; Elke Holinski-Feder; Alexandra Martins; Pål Møller; Eivind Hovig
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

2.  Molecular karyotyping and gene expression analysis in childhood cancer patients.

Authors:  Galetzka Danuta; Müller Tobias; Dittrich Marcus; Endres Miriam; Kartal Nergiz; Sinizyn Olesja; Rapp Steffen; Zeller Tanja; Müller Christian; Hankeln Thomas; Scholz-Kreisel Peter; Chorzempa Heather; Mirsch Johanna; Poplawski Alicia; Rossmann Heidi; Spix Claudia; Haaf Thomas; Prawitt Dirk; Marron Manuela; Schmidberger Heinz
Journal:  J Mol Med (Berl)       Date:  2020-06-23       Impact factor: 4.599

3.  Identification of genetic variants for clinical management of familial colorectal tumors.

Authors:  Mev Dominguez-Valentin; Sigve Nakken; Hélène Tubeuf; Daniel Vodak; Per Olaf Ekstrøm; Anke M Nissen; Monika Morak; Elke Holinski-Feder; Alexandra Martins; Pål Møller; Eivind Hovig
Journal:  BMC Med Genet       Date:  2018-02-20       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.